Entries by Susan Tantawi

Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline

Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced today the successful completion of a $64 million equity financing. This reinforces Galecto’s existing cash balance extending the Company’s cash runway into late 2022.

Galecto Appoints New Chair and Strengthens Board of Directors

Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced today that its Board of Directors has appointed Amit Munshi as its new Chairman. Galecto also announced the appointment of David Shapiro MD, the former Chief Medical Officer of Intercept Pharmaceuticals, to its Board of Directors.

Galecto Appoints Jonathan Freve as Chief Financial Officer

Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the appointment of Jonathan Freve, CPA, as its Chief Financial Officer (CFO).

Galecto and PharmAkea merge to create strong clinical-stage company developing first-in-class therapeutics in fibrosis and cancer

Galecto, the leading developer of galectin modulators for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and cancer, and PharmAkea, Inc., a privately held San Diego-based pharmaceutical company developing novel small molecules against protein targets involved in fibroproliferative disease, today announced the two companies will merge.